Systemic anaplastic large-cell lymphoma: Results from the non-hodgkin's lymphoma classification project

American Journal of Hematology

Volumn 67, Issue 3, 2001, Pages 172-178

  Weisenburger, Dennis D ^a,h   Anderson, James R ^b,c   Diebold, Jacques ^a,b   Gascoyne, Randy D ^d   MacLennan, Kenneth A ^e   Konrad Muller Hermelink H ^f   Nathwani, Bharat N ^g   Ullrich, Fred ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c HÔTEL DIEU   (France)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Anaplastic large cell lymphoma; Anaplastic lymphoma kinase; Diffuse large B cell lymphoma; Non Hodgkin's lymphoma; Peripheral T cell lymphoma; Phenotype

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; T CELL LYMPHOMA;

EID: 0034974798     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.1102     Document Type: Article

References (35)

1. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
2. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation
3. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
4. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997
5. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma
6. Primary Ki-1 anaplastic large-cell lymphoma in adults: Clinical characteristics and therapeutic outcome
7. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies
8. Relation of CD30 expression to survival and morphology in large cell B cell lymphomas
9. 16-year experience at M.D. Anderson Cancer Center with primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large cell lymphoma
10. CD30 (Ki-1)-positive malignant lymphomas: Clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease
11. Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome
12. NPM-ALK: A distinct clinicopathologic entity
13. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1
14. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements
15. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum
16. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
17. Detection of t(2;5) in anaplastic large cell lymphoma. Comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue
18. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation
19. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
20. NPM/ALK expression
21. + anaplastic large-cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology
22. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma
23. + lymphoma: Clinicopathological findings and outcome
24. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
25. Nonparametric estimation from incomplete observations
26. Regression models and life-tables
27. A predictive model for aggressive non-Hodgkin's lymphoma
28. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma
29. Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification
30. Peripheral T-cell lymphomas: An evaluation of reproducibility of the updated Kiel classification
31. Noncutaneous T-cell lymphomas. Recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis
32. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas
33. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma
34. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: Distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor